Patient living with diabetes face many barriers in access to treatment and care. These include capacity and availability of local healthcare resources and professionals; ability of healthcare systems to offer comprehensive diabetes management encompassing treatment of comorbidities; availability of essential supplies; education and support for people with diabetes; and access to affordable, quality medicines.

Another sizeable challenge is the high undiagnosed rate of people living with diabetes in many LMICs. The rate of people living with undiagnosed diabetes (PWUD) represents more than half of all people living with diabetes in those two countries, the highest proportion of all International Diabetes Federation regions.

All this has led to a renewed focus in global and national public health agendas on improving diagnosis, treatment, and control of diabetes (WHO, ATM Foundation and other important organizations).

Sanofi is committed to improving access to diabetes care in low-income and middle-income countries and underserved communities across geographies.

In order to offer solutions adapted to local needs, Sanofi is piloting a new business model in selected low-and middle-income countries to increase access to insulin.  Countries are chosen based on their governments committing to tackle non-communicable diseases (NCDs); the priority of diabetes on their healthcare agenda; and government interest in incorporating analog insulins, now included in the WHO EML (WHO Model List of Essential Medicines).

Our approach includes patient education and support initiatives, capacity building for healthcare professionals, and health system strengthening measures, supported by digital tools and health data, co-created by partnership with local and global multi-disciplinary parties across the value chain and patient journey for better Diabetes care for underserved populations.

This is in full support of the United Nations 2030 Agenda for Sustainable Development Goals and ensuring access to medicines on the WHO EML.